Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. (15th June 2020)
- Record Type:
- Journal Article
- Title:
- Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. (15th June 2020)
- Main Title:
- Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies
- Authors:
- Bajetto, Adriana
Thellung, Stefano
Dellacasagrande, Irene
Pagano, Aldo
Barbieri, Federica
Florio, Tullio - Abstract:
- Abstract: Mesenchymal stem cells (MSCs) can be isolated from bone marrow or other adult tissues (adipose tissue, dental pulp, amniotic fluid, and umbilical cord). In vitro, MSCs grow as adherent cells, display fibroblast-like morphology, and self-renew, undergoing specific mesodermal differentiation. High heterogeneity of MSCs from different origin, and differences in preparation techniques, make difficult to uniform their functional properties for therapeutic purposes. Immunomodulatory, migratory, and differentiation ability, fueled clinical MSC application in regenerative medicine, whereas beneficial effects are currently mainly ascribed to their secretome and extracellular vesicles. MSC translational potential in cancer therapy exploits putative anti-tumor activity and inherent tropism toward tumor sites to deliver cytotoxic drugs. However, controversial results emerged evaluating either the therapeutic potential or homing efficiency of MSCs, as both antitumor and protumor effects were reported. Glioblastoma (GBM) is the most malignant brain tumor and its development and aggressive nature is sustained by cancer stem cells (CSCs) and the identification of effective therapeutic is required. MSC dualistic action, tumor-promoting or tumor-targeting, is dependent on secreted factors and extracellular vesicles driving a complex cross talk between MSCs and GBM CSCs. Tumor-tropic ability of MSCs, besides providing an alternative therapeutic approach, could represent a tool toAbstract: Mesenchymal stem cells (MSCs) can be isolated from bone marrow or other adult tissues (adipose tissue, dental pulp, amniotic fluid, and umbilical cord). In vitro, MSCs grow as adherent cells, display fibroblast-like morphology, and self-renew, undergoing specific mesodermal differentiation. High heterogeneity of MSCs from different origin, and differences in preparation techniques, make difficult to uniform their functional properties for therapeutic purposes. Immunomodulatory, migratory, and differentiation ability, fueled clinical MSC application in regenerative medicine, whereas beneficial effects are currently mainly ascribed to their secretome and extracellular vesicles. MSC translational potential in cancer therapy exploits putative anti-tumor activity and inherent tropism toward tumor sites to deliver cytotoxic drugs. However, controversial results emerged evaluating either the therapeutic potential or homing efficiency of MSCs, as both antitumor and protumor effects were reported. Glioblastoma (GBM) is the most malignant brain tumor and its development and aggressive nature is sustained by cancer stem cells (CSCs) and the identification of effective therapeutic is required. MSC dualistic action, tumor-promoting or tumor-targeting, is dependent on secreted factors and extracellular vesicles driving a complex cross talk between MSCs and GBM CSCs. Tumor-tropic ability of MSCs, besides providing an alternative therapeutic approach, could represent a tool to understand the biology of GBM CSCs and related paracrine mechanisms, underpinning MSC-GBM interactions. In this review, recent findings on the complex nature of MSCs will be highlighted, focusing on their elusive impact on GBM progression and aggressiveness by direct cell-cell interaction and via secretome, also facing the perspectives and challenges in treatment strategies. : Abstract : Diagrammatic representation of the interactions between mesenchymal stem cells and glioblastoma cells, involving also the other nonmalignant stromal and immune cells within the tumor microenvironment. In the figure are highlighted the critical pathways that may support or impair tumor growth via a variety of mechanisms … (more)
- Is Part Of:
- Stem cells translational medicine. Volume 9:Number 11(2020)
- Journal:
- Stem cells translational medicine
- Issue:
- Volume 9:Number 11(2020)
- Issue Display:
- Volume 9, Issue 11 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 11
- Issue Sort Value:
- 2020-0009-0011-0000
- Page Start:
- 1310
- Page End:
- 1330
- Publication Date:
- 2020-06-15
- Subjects:
- cancer stem cells -- extracellular vesicles -- glioblastoma -- mesenchymal stem cells -- secretoma
Stem cells -- Periodicals
Regenerative medicine -- Periodicals
Periodicals
616.0277405 - Journal URLs:
- https://academic.oup.com/stcltm ↗
http://stemcellsjournals.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2157-6580/issues/ ↗
http://stemcellstm.alphamedpress.org/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/sctm.20-0161 ↗
- Languages:
- English
- ISSNs:
- 2157-6564
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25877.xml